elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
radium-223 therapy
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Application
keyword
radium-223 therapy
RIS
0.001
(Research Intensity Score)
Papers
103
Top papers
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
2023 · 37 citations
Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project
2025 · 5 citations
Quantitative hazard visualization of radioisotope contamination risks in emergency settings following radium-223 therapy.
2026
Figure S24 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
2026
Real-world effectiveness and safety of radium-223 therapy in castration-resistant prostate cancer with bone metastases
2026 · 1 citations
Beyond single biomarkers: A composite approach to response assessment in radium-223 therapy
2026
Excellent response after receiving six cylces of Radium-223 Therapy in Multifocal Bone metastatic castration-resistant Prostate Cancer
2026
Fracture risk and survival outcomes of radium-223 therapy for bone metastases in mCRPC and the modulatory role of bone-protective therapy: a systematic review and meta-analysis
2026 · 1 citations
Clinical characteristics and survival outcomes in veterans receiving radium-223 for metastatic castration-resistant prostate cancer.
2026
Newest papers
Quantitative hazard visualization of radioisotope contamination risks in emergency settings following radium-223 therapy.
2026
Figure S24 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
2026
Real-world effectiveness and safety of radium-223 therapy in castration-resistant prostate cancer with bone metastases
2026 · 1 citations
Beyond single biomarkers: A composite approach to response assessment in radium-223 therapy
2026
Excellent response after receiving six cylces of Radium-223 Therapy in Multifocal Bone metastatic castration-resistant Prostate Cancer
2026
Fracture risk and survival outcomes of radium-223 therapy for bone metastases in mCRPC and the modulatory role of bone-protective therapy: a systematic review and meta-analysis
2026 · 1 citations
Clinical characteristics and survival outcomes in veterans receiving radium-223 for metastatic castration-resistant prostate cancer.
2026
Circulating tumor DNA (ctDNA) dynamics in bone-dominant metastatic castration resistant prostate cancer (mCRPC) treated with radium-223 with or without olaparib: Biomarker analyses from the multicenter, randomized, phase 2, investigator-initiated COMRADE trial.
2026
Outcomes of radium-223 therapy in combination with enzalutamide for metastatic castration-resistant prostate cancer: A multicenter retrospective analysis in Japan.
2026
Browse all papers →
radium-223 therapy's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
radium-223 therapy's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link